Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) EBIT Margin (2020 - 2022)

Immuneering (IMRX) has 3 years of EBIT Margin data on record, last reported at 3073628.13% in Q4 2022.

  • For Q4 2022, EBIT Margin fell 306776511.0% year-over-year to 3073628.13%; the TTM value through Sep 2023 reached 12328770.99%, down 1231911346.0%, while the annual FY2022 figure was 16325.77%, 1469661.0% down from the prior year.
  • EBIT Margin reached 3073628.13% in Q4 2022 per IMRX's latest filing, down from 34362.04% in the prior quarter.
  • Across five years, EBIT Margin topped out at 644.66% in Q3 2020 and bottomed at 3073628.13% in Q4 2022.
  • Average EBIT Margin over 3 years is 348631.64%, with a median of 5863.02% recorded in 2021.
  • Peak YoY movement for EBIT Margin: crashed -112735bps in 2021, then tumbled -306776511bps in 2022.
  • A 3-year view of EBIT Margin shows it stood at 644.66% in 2020, then tumbled by -809bps to 5863.02% in 2021, then plummeted by -52324bps to 3073628.13% in 2022.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 3073628.13% in Q4 2022, 34362.04% in Q3 2022, and 12334.43% in Q2 2022.